Cart
sales@molnova.com
Vedolizumab
CAS No. 943609-66-3
Vedolizumab ( —— )
Catalog No. M22145 CAS No. 943609-66-3
Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 485 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameVedolizumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionVedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
-
DescriptionVedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
RecptorIntegrin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number943609-66-3
-
Formula Weight147 kDa
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Soler D, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrintherapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009 Sep;330(3):864-75.
molnova catalog
related products
-
TR-14035
A potent, orally bioavailable, dual α4β7/α4β1 integrin antagonist with IC50 of 7/87 nM.
-
Integrin-IN-27
A potent integrin αvβ3 antagonist with IC50 of 18 nM; could be conjugated to paclitaxel for selective delivery to alphavbeta3 positive metastatic cancer cells.
-
Lifitegrast
A potent LFA-1/ICAM-1 antagonist with IC50 of 9 nM in HuT78 cells; exhibits good in vitro safety profile and low potency on CYP3A4, CYP2C9 and hERG.
